Genetic Tests Identify Risk of Irinotecan-Induced Toxicity: John Logan Black, M.D.
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Genetic Tests Identify Risk of Irinotecan-Induced Toxicity: John Logan Black, M.D.
-
ナレーター：
-
著者：
このコンテンツについて
John Logan Black, M.D., explains how Mayo Clinic Laboratories' UGT1A1 tests (Mayo IDs: U1A1Q and UGTFZ) identify genetic variants that increase the risk of potentially life-threatening reactions to irinotecan, a chemotherapy agent.
(00:32)
Could you give us a brief overview about your background and yourself?
(02:16)
Could you explain the role of the UGT1A1 gene and its significance in the pharmacogenomics of irinotecan?
(05:34)
What specific tests do we offer for UGT1A1 at Mayo Clinic Laboratories?
(08:01)
Can you clarify the difference between targeted genotyping and full gene sequencing, and when each method is most appropriate?
(10:36)
Could you elaborate on the specific clinical indications for testing in relation to irinotecan?
(13:27)
How do UGT1A1 test results impact the dosing of irinotecan? What should clinicians consider when using those results?
(14:02)
Are there any other factors or related genes that should be considered alongside UGT1A1, particularly for cancer therapy?